Skip to main content
Erschienen in: ADHD Attention Deficit and Hyperactivity Disorders 4/2017

15.07.2017 | Erratum

Erratum to: Effects of atomoxetine on attention in Wistar rats treated with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4)

verfasst von: Joachim Hauser, Andreas Reissmann, Thomas-A. Sontag, Oliver Tucha, Klaus W. Lange

Erschienen in: ADHD Attention Deficit and Hyperactivity Disorders | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Excerpt

The present study is a part of a large research project investigating the effects of substances used in the treatment of attention deficit hyperactivity disorder on attention in rats. This paper presents the results for atomoxetine in DSP4-treated rats, while our findings regarding methylphenidate were published previously (Hauser et al. 2017). This reference was not included in the present paper due to the close succession of the two articles’ publication. …
Literatur
Zurück zum Zitat Hauser J, Reissmann A, Sontag TA, Tucha O, Lange KW (2017) Effects of methylphenidate on attention in Wistar rats treated with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4). J Neural Transm 124:643–654CrossRefPubMed Hauser J, Reissmann A, Sontag TA, Tucha O, Lange KW (2017) Effects of methylphenidate on attention in Wistar rats treated with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4). J Neural Transm 124:643–654CrossRefPubMed
Metadaten
Titel
Erratum to: Effects of atomoxetine on attention in Wistar rats treated with the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4)
verfasst von
Joachim Hauser
Andreas Reissmann
Thomas-A. Sontag
Oliver Tucha
Klaus W. Lange
Publikationsdatum
15.07.2017
Verlag
Springer Vienna
Erschienen in
ADHD Attention Deficit and Hyperactivity Disorders / Ausgabe 4/2017
Print ISSN: 1866-6116
Elektronische ISSN: 1866-6647
DOI
https://doi.org/10.1007/s12402-017-0235-8

Weitere Artikel der Ausgabe 4/2017

ADHD Attention Deficit and Hyperactivity Disorders 4/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.